+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oncology Biosimilars Market - Global Forecast 2026-2032- Product Image
Oncology Biosimilars Market - Global Forecast 2026-2032- Product Image
Sale

Oncology Biosimilars Market - Global Forecast 2026-2032

  • Report

  • 194 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4968765
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oncology Biosimilars Market is projected to reach USD 8.66 Billion in 2026. It is expected to continue growing at a CAGR of 13.04%, reaching USD 18.38 Billion by 2032.

Oncology biosimilars are reshaping cancer care by providing highly similar, clinically comparable alternatives to reference biologics used in solid tumors, hematologic malignancies, and supportive care. Regulators, including the U.S. FDA, European Medicines Agency, World Health Organization, and national agencies, require a totality-of-evidence approach covering analytical similarity, pharmacokinetics, immunogenicity, and clinical performance before approval.

Demand is supported by patent expirations for major monoclonal antibodies, pressure on oncology drug budgets, and payer interest in sustainable access. Biosimilars for trastuzumab, bevacizumab, rituximab, and pegfilgrastim have demonstrated that competition can expand treatment affordability while preserving the standards clinicians expect for biologic cancer therapies.

Transformative Shifts in the Oncology Biosimilars Landscape

The landscape is shifting from first-wave biosimilar launches toward lifecycle-based competition, portfolio contracting, and evidence-driven adoption. Hospitals and oncology networks are increasingly evaluating biosimilars through therapeutic interchange protocols, formulary governance, real-world outcomes, and total cost-of-care measures rather than acquisition price alone.

Regulatory maturity is also transforming the market. Europe’s long-standing biosimilar framework, the FDA’s expanding oncology biosimilar approvals, and growing reliance pathways in emerging markets are reducing uncertainty. At the same time, manufacturing scale, supply assurance, physician education, and patient confidence remain decisive differentiators for organizations competing in oncology biologics.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is adding cumulative value across oncology biosimilar development, manufacturing, and commercialization. AI-enabled analytics support cell-line optimization, process monitoring, deviation detection, regulatory intelligence, literature surveillance, and pharmacovigilance signal detection, helping teams manage complex biologic variability with greater speed and consistency.

The impact is strongest when AI complements validated scientific methods rather than replacing them. Regulators continue to rely on robust comparability evidence, quality-by-design controls, and post-market safety monitoring. As FDA and EMA policy discussions on AI in drug development evolve, organizations that pair advanced analytics with transparent governance are better positioned to improve timelines, compliance, and launch execution.

Key Regional Insights Across Major Oncology Biosimilar Markets

North America remains a high-value oncology biosimilars region, led by the United States, where Medicare Part B reimbursement dynamics, integrated delivery networks, oncology practice pathways, and payer contracting influence utilization. Canada is advancing through provincial and pan-Canadian policy mechanisms that increasingly favor cost-effective biologic options while maintaining Health Canada’s rigorous biosimilar review standards.

Europe is the most mature adoption environment, supported by EMA experience dating back to the first EU biosimilar approval in 2006, national tendering, physician familiarity, and established pharmacovigilance systems. Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia combine regulatory modernization with local biologics manufacturing capacity, oncology infrastructure investment, and increasing acceptance of biosimilar monoclonal antibodies. Latin America is growing through ANVISA, COFEPRIS, and regional access initiatives that prioritize affordability and public-sector procurement. The Middle East is advancing through national cancer strategies, hospital modernization, and centralized purchasing, while Africa shows rising demand through oncology capacity building, donor-supported access programs, public procurement, and growing recognition of biosimilars as tools for improving biologic cancer therapy availability.

Key Group Insights for Oncology Biosimilar Adoption

The European Union anchors global biosimilar confidence through harmonized scientific assessment, pharmacovigilance, interchangeability guidance, and widespread tender-based purchasing. G7 countries remain central to clinical evidence generation, reimbursement innovation, advanced oncology care delivery, and premium biologic demand, while NATO members overlap with many high-income health systems focused on supply security, procurement resilience, and uninterrupted access to essential oncology medicines.

BRICS markets are increasingly important because China, India, Brazil, Russia, and South Africa combine large oncology populations with industrial policy supporting biologics manufacturing, technology transfer, and domestic medicine security. ASEAN countries are improving regulatory convergence, reliance pathways, and hospital access to cost-efficient biologics, while the GCC is using centralized procurement, specialist cancer centers, and national oncology strategies to accelerate availability of oncology biosimilars across public and private health systems.

Key Country Insights Shaping Competitive Positioning

The United States remains the largest commercial opportunity, driven by reference biologic spending, oncology network consolidation, Medicare reimbursement rules, and growing clinician experience with FDA-approved biosimilars. Canada is expanding access through provincial reimbursement policies and pan-Canadian review mechanisms, while Mexico is strengthening biosimilar use through public procurement and COFEPRIS oversight. Brazil combines large oncology demand with established ANVISA regulation and public health system purchasing, making it a key Latin American access market.

The United Kingdom, Germany, France, Italy, and Spain benefit from mature oncology infrastructure, specialist prescribing capacity, and national health technology assessment, although adoption varies by tendering, gainsharing, hospital formularies, and prescribing autonomy. Russia emphasizes localized supply and medicine security. China and India are pivotal manufacturing and demand centers, supported by large patient populations, domestic biologics capabilities, and evolving regulatory pathways. Japan, South Korea, and Australia maintain rigorous regulatory standards and strong oncology systems, making them influential reference markets for quality expectations, switching practices, real-world evidence, and physician acceptance.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize oncology biosimilar portfolios around high-burden cancer indications, reference-product loss of exclusivity, regulatory feasibility, and payer willingness to shift volume. Commercial success requires more than price reduction; organizations need reliable supply, oncology-specific medical education, patient support, transparent switching data, and contracting models aligned with provider economics.

Manufacturers should invest in advanced characterization, scalable biologics manufacturing, quality systems, pharmacovigilance readiness, and real-world evidence generation. Partnerships with hospitals, group purchasing organizations, cancer networks, and national health systems can accelerate uptake. In emerging markets, local regulatory expertise, cold-chain reliability, stakeholder education, and affordability programs are essential for sustainable oncology biosimilar adoption.

Research Methodology

The analysis is built on triangulated secondary and primary research. Secondary sources include regulatory databases, product labels, peer-reviewed oncology literature, health technology assessment publications, reimbursement policies, clinical guidelines, pharmacovigilance documents, and guidance from FDA, EMA, WHO, and national authorities.

Market interpretation is validated through expert review of competitive launches, approval pathways, manufacturing capacity, pricing behavior, procurement practices, reimbursement frameworks, and adoption trends. The research applies structured data normalization, cross-source verification, evidence weighting, and quality checks to ensure insights reflect verified, data-backed market behavior rather than unverified assumptions, without relying on market sizing, market share, or forecasting.

Conclusion

Oncology biosimilars have moved from proof-of-concept to an established pillar of cancer-care affordability. Their continued adoption is supported by regulatory confidence, expanding clinical familiarity, payer pressure, public procurement, and the ongoing need to manage biologic oncology spending without compromising treatment standards.

The next phase will reward organizations that combine scientific rigor, manufacturing reliability, AI-enabled operational efficiency, strong pharmacovigilance, and region-specific market access strategies. Stakeholders that build trust with oncologists, payers, regulators, pharmacists, and patients will be best positioned to capture long-term value in the global oncology biosimilars market.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Oncology Biosimilars Market, by Product Type
7.1. Introduction
7.2. Monoclonal Antibodies
7.2.1. Rituximab
7.2.2. Trastuzumab
7.2.3. Bevacizumab
7.3. Hormonal Therapies
7.4. Growth Factors
7.4.1. Filgrastim
7.4.2. Pegfilgrastim
8. Oncology Biosimilars Market, by Therapeutic Indication
8.1. Introduction
8.2. Breast Cancer
8.3. Colorectal Cancer
8.4. Gastric Cancer
8.5. Lung Cancer
8.6. Non-Hodgkin's Lymphoma
9. Oncology Biosimilars Market, by Route Of Administration
9.1. Introduction
9.2. Intravenous Infusion
9.3. Subcutaneous Injection
10. Oncology Biosimilars Market, by Patient Age Group
10.1. Introduction
10.2. Pediatric Patients
10.3. Adult Patients
10.4. Geriatric Patients
11. Oncology Biosimilars Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
11.5. Specialty Pharmacies
12. Oncology Biosimilars Market, by Region
12.1. Asia-Pacific
12.2. North America
12.3. Latin America
12.4. Europe
12.5. Middle East
12.6. Africa
13. Oncology Biosimilars Market, by Group
13.1. ASEAN
13.2. GCC
13.3. European Union
13.4. BRICS
13.5. G7
13.6. NATO
14. Oncology Biosimilars Market, by Country
14.1. United States
14.2. Canada
14.3. Mexico
14.4. Brazil
14.5. United Kingdom
14.6. Germany
14.7. France
14.8. Russia
14.9. Italy
14.10. Spain
14.11. China
14.12. India
14.13. Japan
14.14. Australia
14.15. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. FPNV Positioning Matrix, 2025
15.3. Market Concentration Analysis, 2025
15.3.1. Concentration Ratio (CR)
15.3.2. Herfindahl Hirschman Index (HHI)
15.4. Recent Developments & Impact Analysis, 2025
15.5. Product Portfolio Analysis, 2025
15.6. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Accord Healthcare Ltd.
16.2. Alkem Laboratories Ltd.
16.3. Amgen Inc.
16.4. Apotex Inc.
16.5. BIOCAD
16.6. Biocon Biologics Limited
16.7. Celltrion Inc.
16.8. Coherus BioSciences, Inc.
16.9. Dr. Reddy’s Laboratories Ltd.
16.10. Henlius Biopharmaceuticals Co., Ltd.
16.11. Hospira Inc.
16.12. Intas Pharmaceuticals Ltd.
16.13. Novartis International AG
16.14. Organon & Co.
16.15. Pfizer Inc.
16.16. Sandoz Group AG
16.17. STADA Arzneimittel AG
16.18. Teva Pharmaceutical Industries Ltd.
16.19. Viatris Inc.
16.20. Zydus Lifesciences Ltd.
List of Figures
FIGURE 1. GLOBAL ONCOLOGY BIOSIMILARS MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL ONCOLOGY BIOSIMILARS MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL ONCOLOGY BIOSIMILARS MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2032 (%)
FIGURE 9. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 11. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
FIGURE 13. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 19. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 21. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 23. GLOBAL ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL ONCOLOGY BIOSIMILARS MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL MONOCLONAL ANTIBODIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL RITUXIMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL RITUXIMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL RITUXIMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL TRASTUZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL TRASTUZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL TRASTUZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL BEVACIZUMAB MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL BEVACIZUMAB MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL BEVACIZUMAB MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL HORMONAL THERAPIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL GROWTH FACTORS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL GROWTH FACTORS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL GROWTH FACTORS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL FILGRASTIM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL FILGRASTIM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL FILGRASTIM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL PEGFILGRASTIM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL PEGFILGRASTIM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL PEGFILGRASTIM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL GASTRIC CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL GASTRIC CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL GASTRIC CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL NON-HODGKIN'S LYMPHOMA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL NON-HODGKIN'S LYMPHOMA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL NON-HODGKIN'S LYMPHOMA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL INTRAVENOUS INFUSION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL SUBCUTANEOUS INJECTION MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL GERIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL SPECIALTY PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 77. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 78. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 79. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 80. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 81. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 82. ASIA-PACIFIC ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 83. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 84. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 85. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 86. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 87. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 88. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 89. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 90. NORTH AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 91. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 93. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 94. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 95. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 96. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 97. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 98. LATIN AMERICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 99. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 100. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 101. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 102. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 103. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 104. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 105. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 106. EUROPE ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 107. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 109. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 110. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 111. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 112. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 113. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 114. MIDDLE EAST ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 115. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 116. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 117. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 118. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 119. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 120. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 121. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 122. AFRICA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 123. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 124. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 125. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 126. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 127. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 128. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 129. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 130. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 131. ASEAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 132. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 133. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 134. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 135. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 136. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 137. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 138. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 139. GCC ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 140. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 141. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 142. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 143. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 144. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 145. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 146. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 147. EUROPEAN UNION ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 148. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 149. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 150. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 151. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 152. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 153. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 154. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 155. BRICS ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 157. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 158. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 159. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 160. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 161. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 162. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 163. G7 ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 164. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 165. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 166. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 167. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 168. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 169. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 170. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 171. NATO ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 172. GLOBAL ONCOLOGY BIOSIMILARS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 173. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 174. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 175. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 176. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 177. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 178. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 179. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 180. UNITED STATES ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 181. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 182. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 183. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 184. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 185. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 186. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 187. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 188. CANADA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 189. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 190. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 191. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 192. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 193. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 194. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 195. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 196. MEXICO ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 197. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 198. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 199. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 200. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 201. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 202. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 203. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 204. BRAZIL ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 205. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 206. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 207. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 208. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 209. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 210. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 211. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 212. UNITED KINGDOM ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 213. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 214. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 215. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 216. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 217. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 218. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 219. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 220. GERMANY ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 221. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 222. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 223. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 224. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 225. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 226. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 227. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 228. FRANCE ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 229. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 230. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 231. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 232. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 233. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 234. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 235. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 236. RUSSIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 237. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 238. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 239. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 240. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 241. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 242. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 243. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 244. ITALY ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 245. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 246. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 247. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 248. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 249. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 250. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 251. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 252. SPAIN ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 253. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 254. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 255. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 256. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 257. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 258. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 259. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 260. CHINA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 261. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 262. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 263. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 264. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 265. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 266. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 267. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 268. INDIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 269. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 270. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 271. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 272. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 273. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 274. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 275. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 276. JAPAN ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 277. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 278. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 279. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 280. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 281. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 282. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 283. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 284. AUSTRALIA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 285. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 286. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PRODUCT TYPE, 2017-2032 (USD MILLION)
TABLE 287. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2017-2032 (USD MILLION)
TABLE 288. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY GROWTH FACTORS, 2017-2032 (USD MILLION)
TABLE 289. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY THERAPEUTIC INDICATION, 2017-2032 (USD MILLION)
TABLE 290. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 291. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY PATIENT AGE GROUP, 2017-2032 (USD MILLION)
TABLE 292. SOUTH KOREA ONCOLOGY BIOSIMILARS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 293. GLOBAL ONCOLOGY BIOSIMILARS MARKET SHARE, BY KEY PLAYER, 2025
TABLE 294. GLOBAL ONCOLOGY BIOSIMILARS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

Companies Mentioned

  • Accord Healthcare Ltd.
  • Alkem Laboratories Ltd.
  • Amgen Inc.
  • Apotex Inc.
  • BIOCAD
  • Biocon Biologics Limited
  • Celltrion Inc.
  • Coherus BioSciences, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Henlius Biopharmaceuticals Co., Ltd.
  • Hospira Inc.
  • Intas Pharmaceuticals Ltd.
  • Novartis International AG
  • Organon & Co.
  • Pfizer Inc.
  • Sandoz Group AG
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.

Table Information

Report AttributeDetails
No. of Pages194
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 8.66 Billion
Forecasted Market Value ( USD ) by 2032 $ 18.38 Billion
Compound Annual Growth Rate13.0%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Biosimilars Market - Global Forecast 2026-2032 - Product Image

Biosimilars Market - Global Forecast 2026-2032

  • Report
  • 180 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032 - Product Image

Biosimilar Monoclonal Antibodies Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Oncology Biosimilars - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Oncology Biosimilars - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From
Oncology Biosimilars Market - Product Image

Oncology Biosimilars Market

  • Report
  • 173 Pages
  • Global
From
Oncology Biosimilars Market Report by Drug Type, Cancer Type, Distribution Channel, and Region 2026-2034 - Product Image

Oncology Biosimilars Market Report by Drug Type, Cancer Type, Distribution Channel, and Region 2026-2034

  • Report
  • 149 Pages
  • Global
From

About the Oncology Biosimilars Market

Oncology Biosimilars are biotechnology-based drugs that are designed to replicate the therapeutic effects of existing biologic drugs used to treat cancer. These drugs are developed using advanced biotechnology techniques, such as recombinant DNA technology, to create a molecule that is similar to the original biologic drug. Oncology Biosimilars are intended to provide a cost-effective alternative to the original biologic drug, while still providing the same therapeutic benefits. Oncology Biosimilars are regulated by the FDA and must meet the same safety and efficacy standards as the original biologic drug. The approval process for Oncology Biosimilars is more rigorous than that of generic drugs, as the FDA requires additional clinical trials to demonstrate the safety and efficacy of the drug. Oncology Biosimilars are becoming increasingly popular as a cost-effective alternative to the original biologic drugs. As the cost of biologic drugs continues to rise, Oncology Biosimilars offer a more affordable option for patients. Some companies in the Oncology Biosimilars market include Amgen, Pfizer, Merck, and Novartis. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.